The Long-Term Sequelae and Clinical Workload Resulting from Toxicities of Immune Checkpoint Inhibitor (ICI) Therapy in Patients with Cancer - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Long-Term Effects and Clinical Burden Associated with Immune Checkpoint Inhibitor Toxicities in Cancer Patients

  • By

  • Veera Nurmela

  • Anni Juntunen

  • Satu Tiainen

  • Janne Martikainen

  • Sanna Pasonen-Seppänen

  • Aino Rönkä

  • June 23, 2026

Share

  • 1

    61% of patients with immune-related adverse events (irAE) experienced chronic toxicity lasting over 12 weeks.

  • 2

    43% of irAEs required corticosteroid treatment, with 49% of these patients undergoing prolonged therapy exceeding 12 weeks.

  • 3

    Management of irAEs necessitated an average of 5.3 contacts with a medical oncologist per irAE.

  • 4

    Chronic irAEs often involve irreversible organ damage and may require complex management strategies.

  • 5

    The study analyzed the burden of chronicity and challenges of corticosteroid therapy in patients treated with immune checkpoint inhibitors.

Original Source(s)

The Long-Term Sequelae and Clinical Workload Resulting from Toxicities of Immune Checkpoint Inhibitor (ICI) Therapy in Patients with Cancer

  • by Veera Nurmela, Anni Juntunen, Satu Tiainen, Janne Martikainen, Sanna Pasonen-Seppänen, Aino Rönkä

  • June 23, 2026

Related Content

Decoding cancer-associated ribosomal protein mutations: A new frontier in cancer and ribosome biology

Posterior fossa ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes (Part I of ependymomas across compartments)

Spinal ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes with a focus on the pediatric population (Part III of ependymomas across compartments)